Stocktwits report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
Why INGN Stock advanced +0.15% Today — RQD Quant Desk Flash
Inogen Inc (INGN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is INGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Inogen Inc (NASDAQ: INGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $6.87 (+0.15% 1D, market cap $182.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, INGN ranks #597 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does INGN compare to SMTI and AGPU in the Health Care sector?
▼
Within the Health Care sector (Industrial Specialties), INGN carries a Roarable D- (35/100 RQD), trailing P/E of 8.5x, gross margin of 52.2%, and ROIC of -27.0%. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (55/100 RQD, P/E 8.1x, ROIC 16.3%, cap $301.6M) and AGPU (Axe Compute Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $92.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for INGN?
▼
Per INGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001294133), Inogen Inc generated $295.3M in revenue (+5.9% YoY), $22.7M in net income, and -$13.7M in free cash flow against $298.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±8.1% realized swing band)
Altman Z-Score 1.46 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
Capital intensity & 0% operating margin leave 16 pts on the table
⚔️ Adversarial Opposing Case: What Could Spark a INGN Turnaround Squeeze
While INGN currently carries a cautious 35/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.90) and Max Pain ($7.21) forces dealer call-delta covering toward $8.70.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why INGN Stock advanced +0.15% Today — RQD Quant Desk Flash
Inogen Inc (INGN) advanced +0.15% to $6.87, trading at 56% of its 52-week range ($5.05 – $8.29). Stretched risk/reward at 9x P/E (-27% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 56% of its 52-week range ($5.05 – $8.29) with RSI-14 at 57.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.1% around $6.87 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52.2% gross margin and $0 annual free cash flow.
Seeking Alpha report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
Business Wire report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
For questions about this article or underlying research, email help@trefis.com.
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INGN)
- ✓Walkthrough of INGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
INGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INGN. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INGN)
1. Head-to-Head Health Care Peer Comparison (INGN vs. SMTI, AGPU, ZJYL, LAKE)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Inogen Inc (INGN) ranks #597 by composite RQD confidence (35/100, grade D-) and #587 by equity capitalization ($182.1M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. SMTI currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with INGN at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INGN
ACTIVE
Inogen Inc | D- | 35/100 | 8.5x | 52.2% | -27.0% | +0.15% | $182.1M | Benchmark Subject |
| SMTI Sanara MedTech Inc. | D+ | 55/100 | 8.1x | 92.7% | 16.3% | -2.31% | $301.6M | /smti-vs-ingn → |
| AGPU Axe Compute Inc. | D- | 42/100 | — | — | -35.0% | -4.87% | $92.7M | /agpu-vs-ingn → |
| ZJYL JIN MEDICAL INTERNATIONAL LTD. (Class A) | D | 46/100 | — | 29.2% | — | -6.38% | $371.8M | /zjyl-vs-ingn → |
| LAKE Lakeland Industries Inc. | E | 26/100 | — | 32.9% | -9.5% | +1.82% | $87.3M | /lake-vs-ingn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001294133 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inogen Inc (INGN) reported GAAP revenue of $295.3M (+5.9% vs. FY2024 revenue of $278.8M , and +17.4% cumulative change since FY2023) , GAAP net income of $22.7M, operating cash flow of -$11.2M, and free cash flow of -$13.7M (-637.9% YoY). On the balance sheet, INGN closed FY2025 with $298.6M in total assets against $0 in total debt (Altman Z-Score: 1.46, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $295.3M | $22.7M | -$11.2M | -$13.7M | $298.6M | — |
| FY2024 (FY) | 2024-12-31 | $278.8M | $35.9M | $5.9M | $2.6M | $296.2M | — |
| FY2023 (FY) | 2023-12-31 | $251.6M | $102.4M | -$3.2M | -$3.2M | — | — |
3. INGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Inogen Inc (NASDAQ: INGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $6.87 (+0.15% 1D, market cap $182.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, INGN ranks #597 in composite RQD confidence.
How does INGN compare to SMTI and AGPU in the Health Care sector?
Within the Health Care sector (Industrial Specialties), INGN carries a Roarable D- (35/100 RQD), trailing P/E of 8.5x, gross margin of 52.2%, and ROIC of -27.0%. By comparison, SMTI (Sanara MedTech Inc.) holds a D+ grade (55/100 RQD, P/E 8.1x, ROIC 16.3%, cap $301.6M) and AGPU (Axe Compute Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $92.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INGN?
Per INGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001294133), Inogen Inc generated $295.3M in revenue (+5.9% YoY), $22.7M in net income, and -$13.7M in free cash flow against $298.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INGN trading relative to its 50-day, 200-day, and 52-week technical levels?
INGN last traded at $6.87 (+0.15% on volume of 339,506 shares), positioning the stock +16.44% above its 50-day simple moving average ($5.90) and +10.27% above its 200-day simple moving average ($6.23). Across its 52-week range of $5.05 to $8.29, INGN sits at the 56.2% percentile with a 14-day RSI of 57.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.1% ($6.31 to $7.43).
INGN — Inogen Inc: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
Inogen Inc (INGN) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.87 (+0.15% 1D, market capitalization $182.1M).
- Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -27.0%, gross margin of 52.2%, operating margin of -10.2%, and free cash flow yield of -7.13%.
- Whale 13F & Options Flow (13/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.46, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Inogen Inc (INGN) is a NASDAQ-listed issuer classified under the Health Care sector and the Industrial Specialties industry. Per the financials, the company reported revenue of $295.3M for FY 2025, indicating an operating business of meaningful scale relative to its market capitalization.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Inogen Inc (INGN) reported $295.3M in annual revenue (up from $278.8M in FY2024, +5.9% YoY) and $22.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($251.6M revenue, $102.4M net income) through FY2025, INGN scaled operating cash flow to -$11.2M and free cash flow to -$13.7M, backed by $298.6M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.13% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $5.05 – $8.29 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 8.5x trailing P/E against -10.2% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The source data therefore contains no upstream or downstream dependency mapping, no sector correlation data, and no identified 2nd-order bottlenecks. A prospective investor should recognize that this section cannot confirm supply-chain exposure in either direction.
- Key Question #1: Can INGN sustain or expand its -10.2% operating margin and -27.0% ROIC against Industrial Specialties peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $295.3M and free cash flow of -$13.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is INGN's 7.9x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
INGN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Inogen Inc (INGN) • Click "Debate This Headline" to argue it in the Roar Pit below
Stocktwits report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
Business Wire report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Inogen Inc (INGN) market action, institutional positioning, and fundamental catalysts.
INGN Bull vs. Bear Conversation Board — What's Your Call at $6.87?
Institutional accumulation (14/20 whale flow) and a low forward P/E of 7.9 suggest positioning and valuation support despite weak funda
Long INGN at $6.86 targeting $8.23. Institutional accumulation (14/20 whale flow) and a low forward P/E of 7.9 suggest positioning and valuation support despite weak fundamentals.. Institutional whale score is 13/20 and the risk/reward vs. the $5.05 52-week low is skewed heavily in favor of bulls.
@FadeTheHype Shorting a 13/20 institutional whale-flow stock at $6.86 is dangerous when funds are rotating into Health Care.
A -27% ROIC, -7.13% FCF yield, and a 1/20 cash engine score show the business is consuming capital, with a Simply Wall St RISK WATCH fl
Sitting on the sidelines or leaning short INGN above $6.86. A -27% ROIC, -7.13% FCF yield, and a 1/20 cash engine score show the business is consuming capital, with a Simply Wall St RISK WATCH flag on top.. Until Fundamental Cash Engine (1/20) and FCF yield (-7.13%) inflect higher, upside is capped near $8.29.